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ABSTRACT
Objective Abatacept is a biological disease-modifying
antirheumatic drug (DMARD) used for the treatment of
rheumatoid arthritis (RA) and modulates the costimulatory
signal by cluster of differentiation (CD)28:CD80/CD86
interaction required for T cell activation. Since CD28-
mediated signalling regulates many T cell functions
including cytokine production of, for example, interferons
(IFNs), it is of interest to clarify, whether response to
abatacept has an effect on the IFN inducible
immunoproteasome, as a central regulator of the immune
response.
Methods Effects of abatacept on the proteasome were
investigated in 39 patients with RA over a period of
24 weeks. Using real-time PCR, transcript levels of
constitutive and corresponding immunoproteasome
catalytic subunits were investigated at baseline (T0), week
16 (T16) and week 24 (T24) in sorted blood cells.
Proteasomal activity and induction of apoptosis after
proteasome inhibition were also evaluated.
Results Abatacept achieved remission or low disease
activity in 55% of patients at T16 and in 70% of patients at
T24. By two-way analysis of variance (ANOVA), a significant
reduction of proteasome immunosubunit β1i was shown
only in CD4+ and CD8+ T cells of sustained responders at
both T16 and T24. One-way ANOVA analysis for each
response group confirmed the results and showed
a significant reduction at T24 in CD4+ and CD8+ T cells of
the same group. Abatacept did not influence chymotrypsin-
like activity of proteasome and had no effect on induction of
apoptosis under exposure to a proteasome inhibitor in vitro.
Conclusion The reduction of proteasome immunosubunit
β1i in T cells of patients with RA with sustained response to
abatacept suggests association of the immunoproteasome
of T cells with RA disease activity.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic and
systemic autoimmune disease characterised
by synovial inflammation and progressive
joint destruction.1 As known, activated
T cells play a central role in the pathogenesis
of RA.2 Full T cell activation requires at least
two signals, the initial recognition of the T cell
receptor to its antigen presented by major
histocompatibility complex (MHC) on anti-
gen-presenting cells (APCs), followed by
a second costimulatory signal accomplished
by the binding of cluster of differentiation
(CD)80 and/or CD86 on the surface of APCs
to the CD28 receptor on T cells.3 Shortly after
activation, T cells express cytotoxic T-lympho-
cyte-associated protein 4 (CTLA-4), which
binds to CD80 and CD86 with higher affinity
and avidity than CD28 and transmits an inhi-
bitory signal to suppress T cell activation, and
thus functions as a negative regulator of
T-cell-mediated immune responses.4
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What is already known about this subject?
► Excellent effectiveness of abatacept in improving the
signs and symptoms of rheumatoid arthritis,
especially in patients without prior exposure to
biological disease-modifying anti-rheumatic drugs
(bDAMRDs).
What does this study add?
► A significant reduction of the expression of the
proteasome immunosubunit β1i was observed
exclusively in CD4+ and CD8+ T lymphocytes only
in patients with a prolonged response over 24 weeks
of treatment. This effect is consistent with the mode
of action of abatacept as a costimulation modulator
and inhibitor of T cell activation.
How might this impact on clinical practice?
► The described association between reduction of IFN-
inducible proteasome immunosubunit β1i and
prolonged response to the T- cell-directed therapy
with abatacept call the attention to the apparent link
between the response to abatacept and the
immunoproteasome system.
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Abatacept is a therapeutic alternative for patients with
RA refractory to conventional synthetic or biological dis-
ease-modifying antirheumatic drugs (cs-DMARDs or b--
DMARDs).5 Abatacept (CTLA4-Ig—Orencia, Bristol
Myers Squibb, New York, USA) is a recombinant
bDMARD consisting of the extracellular domain of
human CTLA4 and a fragment of the Fc portion of
human IgG1 (hinge and CH2 and CH3 domains). It
binds CD80/CD86 more strongly than CD28, thereby
blocking interaction with CD28 and inhibiting T cell
activation.6 Nevertheless, it is not yet clear why some
patients do not respond to abatacept therapy or why
others show a loss of response. In order to improve our
therapeutic strategies in RA, it is of great importance to
investigate the pathways behind these different
outcomes.
Ubiquitin proteasome system (UPS) is a non-lysosomal,
multicatalytic and multisubunit protease complex
involved in the ubiquitin (Ub)-dependent and Ub-
independent selective intracellular degradation of pro-
teins and in the generation of peptides presented by the
MHC class I receptor to the antigen receptors of cytotoxic
T cells.7 UPS is a common regulatory modification system
since cell proteins involved in the regulation of basic
cellular processes, such as proliferation, differentiation,
cell cycling and apoptosis, undergo processing and func-
tional limitation by proteasome degradation.8 9 Protea-
some complexes consist of a 20S catalytic core particle
either alone or associated with one or two regulatory
particles (RPs) that can be of identical or different pro-
tein composition. Four activators have been identified in
mammals: 19S RP, PA28 (PA28αβ and PA28γ) and
PA200.10 Enzymatically active proteasome, the 26S pro-
teasome, is made up of a catalytic core particle 20S
capped at one or both ends by 19S RPs. Hybrid protea-
somes are formed when the 20S is capped with two differ-
ent regulators, mainly 19S RP and PA28 (11S).The 20S
proteasome is a hollow cylindrical particle consisting of
four stacked heptametrical rings, two outer α-rings and
two inner β-rings. The two β-rings each harbour three
different constitutive subunits β1, β2 and β5, responsible
for three main proteasome proteolytic activities such as
caspase-like, trypsin-like and chymotrypsin-like,
respectively.11
During immune response, interferon-γ (IFN-γ) partially
or totally induces the substitution of the three constitutive
subunits by their counterpart immunosubunits β1i, β2i
and β5i, respectively, leading to the formation of the so-
called immunoproteasome.12 Similarly, IFN-γ induces the
synthesis of PA28 (11S) regulator (REG) which was iden-
tified as another protein activator of the latent 20S
proteasome.13
During the last 20 years, our group has focused on the
work regarding the involvement of the UPS in patients
with rheumatic diseases with interesting novel findings.
Elevated levels of circulating proteasomes and autoan-
tibodies against proteasomal subunits were detected in
patients with autoimmune diseases including RA.14 15
Thus, we could confirm an upregulation of certain
inducible catalytic subunits of proteasome as well as its
immune activator PA28γ in patients with systemic auto-
immune diseases including systemic lupus erythemato-
sus, autoimmune myositis, Sjögren’s syndrome and
RA.16–19 Furthermore, we found a correlation between
PA28γ serum levels and disease activity in patients with RA
under treatment with abatacept.20
Taken together, the proteasome is not only manifold
linked to basic cellular functions including protein
homoeostasis, cell cycle control and regulation of the
immune system, but can be also involved in the pathogen-
esis of autoimmune and autoinflammatory diseases in
humans. Since abatacept was also shown to modify the
cytokinemilieu including IFN-γ in patients with RA,21 this
in vitro study will focus on the expression and function of
the proteolytic core complex in patients undergoing aba-
tacept treatment.
Patients
The study consisted of a 24-week open-label, non-
interventional treatment of patients with diagnosed RA
fulfiling the criteria for therapy with abatacept. Patients
were treated as standard of care, receiving 500–1000 mg
(body-weight-adjusted) abatacept intravenously at base-
line (T0), week 2, week 4 and every 4 weeks or 125 mg
subcutaneously every week. As comedications, all patients
received methotrexate (MTX) with or without other syn-
thetic DMARDs, glucocorticosteroids and/or non-
steroidal anti-inflammatory drugs. The study was
approved by the local ethics committee of the rheumatol-
ogy and clinical immunology department at the Charité
University Hospital in Berlin, and all patients gave
informed consent prior to blood sample collection. At
T0 and every 12 weeks, patients received routine clinic
and blood examination. Additionally, at T0, at week 16
(T16) and at week 24 (T24), blood samples were taken to
measure proteasome expression at the transcript level
in vitro. As comparator groups, whole-blood transcrip-
tome data of patients with RA from the open-access data-
base Gene Expression Omnibus (http://www.ncbi.nlm.
nih.gov/geo/) were investigated. The selection included
RA responders treated with a first-line DMARD MTX
(n=10), in addition to two responder groups treated
with biological targeting tumour necrosis factor inflixi-
mab (IFX) (n=12) or interleukin 6 receptor tocilizumab
(TCZ) (n=12); the transcriptomes were measured at mul-
tiple time points during 6 months of treatment
(GSE93777).22
METHODS
Isolation of peripheral blood mononuclear cells (PBMCs) and
cellular subsets
Peripheral blood mononuclear cells (PBMCs) from whole
blood were separated through density gradient centri-
fugation using Ficoll separating solution with density of
1.077 g/mL (Biochrom, Berlin, Germany). For isolation
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of blood cell subsets, PBMCs were divided into two frac-
tions. The first one was used for separation of dendritic cells
(DCs) by magnetic cell sorting using Blood Dendritic Cell
Isolation KitII (Miltenyi Biotec, Germany) and the second
fraction was used for isolation of T lymphocytes (CD4+ and
CD8+), B lymphocytes (CD19+) and monocytes (CD14+)
by fluorescence-activated cell sorting (FACS).
For this purpose, PBMCs were incubated with allo-
phycocyanin anti-CD3+ (clone HIT3a), PE-Cy5 anti-
CD4+ (clone OKT4), PE-Cy7 anti-CD8+ (clone
HIT8a), phycoerythrin anti-CD19+ (cloneHIB19)
and fluorescein-isothiocyanate anti-CD14+ (clone
M5E2) (all from BioLegend, Germany). In order to
assess cell viability, 4ʹ, 6-diamidino-2-phenylindole
(Applichem, Germany) was added to the cells. Gated
CD3+ T lymphocytes were used to isolate D4+ and
CD8+ T lymphocytes, while non-CD3+ cells were used
to isolate CD19+ B lymphocytes and CD14+ monocytes.
Cells were sorted by a FACSDiVa flow cytometer.
After sorting, collected cells were washed and two-thirds
of cells were used for RNA isolation and lysed in cell lysis
buffer (Macherey-Nagel, Düren, Germany) containing β-
mercaptoethanol (Carl Roth, Germany), and the other
third was used to estimate the proteolytic activity and
apoptosis after proteasome inhibition.
Measurement of proteolytic activity and apoptosis after
proteasome inhibition
Total PBMCs, CD4+ and CD8+ T lymphocytes were incu-
bated (14 hours, 37°C, 5% CO2) with the proteasome
inhibitor bortezomib at final concentrations of 5.0 and
50.0 nM in 50 µL medium (RPMI 1640 culture medium,
10% fetal calf serum (FCS)) (Biochrom). Cells without
inhibitor served as negative controls.
For measurement of proteasome activity after inhibition
with bortezomib, cells were lysed in 100 µL of 50 mM Tris
HCL (pH 7.4), 150 mM NaCl, 5 mM MgCl2, 1 mM EDTA,
250 mM sucrose, 0.1% Triton X-100 and 1 mM DTT (all
from Sigma, Germany) and incubated for 20 min on ice.
To estimate the remaining chymotrypsin-like activity
of proteasome, lysates were incubated for 2 hours at
37°C with 100 μM fluorogenic substrate N-succinyl-Leu
-Leu-Val-Tyr-AMC (7-amino-4-methylcoumarin) dis-
solved in assay buffer 25 mM HEPES (pH 7.4),
0.5 mM EDTA and 0.03% sodium dodecyl sulfate
(SDS). The assay was done in duplicate in 96-well
black plates (Greiner, Germany) and the released
AMC was detected by fluorescence emission at 460 nm
(excitation at 360 nm) using a Synergy HT microplate
reader (Biotek, USA). For analysis, data were normalised
based on activity from cell lysates without proteasome
inhibitor, which was set as 100%.
Assessment of induction of apoptosis after proteasome
inhibition was performed based on the activity of caspase-
3 and caspase-7 by using the ApoOne Assay kit (Promega,
Germany). For analysis, 50 µL ApoOne caspase 3/7 buf-
fer containing 1% substrate were incubated with cells in
duplicate for 2 hours at 37°C. Etoposide (100 µM,
Biomol, Germany) was used as apoptosis control. Caspase
activity was measured at Ex 485/Em 528 nm using
Synergy HT microplate reader (Biotek). For analysis,
data were normalised based on the caspase activity in
cells without proteasome inhibitor, which was set as 1.00.
Investigation of proteasome expression in PBMCs and all
sorted cells
RNA isolation and reverse transcription into cDNA
Isolation of RNA from blood cells was done by using
NucleoSpin RNA/Protein kit (Macherey-Nagel). Quality
and quantity of RNA were controlled using a NanoDrop
1000 spectrophotometer (Thermo Scientific, Germany).
To synthesise first-strand complementary (cDNA) from
total RNA, SuperScript III First-Strand Synthesis System
for reverse transcriptase-polymerase chain reaction (RT-
PCR) (Invitrogen, Karlsruhe, Germany) was used accord-
ing to the instructions of the manufacturer. The cDNA was
used as a template for the specific primers in real-time PCR.
Relative quantification of gene expression at the mRNA level
Real-time quantitative RT-PCR was used for relative
quantification of gene expression of the proteasome
system, including the three constitutive catalytic beta
subunits β1, β2 and β5 and the corresponding immuno-
subunits β1i, β2i and β5i as well as the constitutive α3
subunit.
For relative quantification, primers were designed for
three housekeeping genes (HKG), beta-actin (ACTB),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
and hypoxanthine guanine phosphoribosyl transferase 1
(HPRT1). Primers for PCR were designed using the pri-
mer 3 software (Version 0.4.0, Whitehead Institute for
Biomedical Research, Cambridge, Massachusetts, USA)
as described elsewhere.23 SYBR Green PCR Master Mix
(Applied Biosystems) was used in amplification reactions
with 200 nM forward and reverse primers for each gene,
in addition to the cDNA. Real-time PCRwas performed by
using the StepOnePlus Real-Time PCR system (Applied
Biosystems).The expression of each target gene at the
mRNA level was measured relative to the reliable HKG
and calculated as R=ECt housekeeping gene/ECt target gene,24
with E representing the amplification efficiency of the
respective primer system.
Identification of the most stable housekeeping gene
Three different statistical algorithms geNorm,25
NormFinder26 and BestKeeper27 were used according to
the developer’s recommendations to evaluate the expres-
sion stability of our three candidate HKGs. For each cell
subset, the mean Ct value for each HKG for each sample
was calculated and used either directly to estimate its
expression stability across all samples as in BestKeeper
algorithm, or was first transformed to relative quantities
using the comparative Ct method as in geNorm and
NormFinder.
GAPDH was shown to represent the most stable refer-
ence gene in all cell subsets and therefore was selected as
Rheumatoid arthritis
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HKG for relative quantifications. The respective ranking
order of the three candidate HKGs using the three algo-
rithms for all cell subsets is shown in table 1. Lower
M values in geNorm and lower stability values in Norm-
Finder indicate the more stably expressed genes. In Best-
Keeper, higher correlation coefficient values correspond
to more stable genes.
Evaluation of serum IFN-γ
The concentration of serum IFN-γ was evaluated using
Human IFN-γ ELISA Kit (BioLegend).
Statistics
According to EULAR response criteria, 28-joint disease
activity score based on erythrocyte sedimentation rate
(DAS28-ESR) was used to identify disease activity for all
patients at T0, T16 and T24 and DAS28≤3.2 was inter-
preted as low, 3.2<DAS28≤5.1 moderate and DAS28>5.1
high.28 A DAS28<2.6 corresponds to being in remission
according to preliminary criteria of the American
Rheumatology Association.29 A good EULAR response
to treatment was defined as an improvement of DAS28-
ESR>1.2 from T0 to T16 (RT16) or T24 (RT24).28 For
statistical analysis, logarithmic normal distributed data
were used for all PCR results that did not fully fit
a normal distribution and extreme outliers were
removed. To analyse the effect of time of treatment
(T0, T16 and T24), response rate (responder and non-
responder (NR)) and the interaction between these
two factors on the expression of different proteasome
subunits and on the concentration of IFN-γ, two-way
(two factors) repeated measure analysis of variance
(ANOVA) with Tukey’s multiple comparison test
(95% CI) was used. To evaluate the effect of time on
the expression of proteasome subunits for each group,
paired one-way ANOVA with Tukey’s multiple compar-
ison test (95% CI) was applied. To estimate the effect
of time, response rate and interaction of both on the
activity of proteasome and apoptosis after inhibition
with bortezomib, unpaired two-way ANOVA was
applied. Per-protocol analyses were applied; thus, only
those patients who strictly adhered to the protocol were
included in all statistical analyses. To evaluate the effect
of MTX, IFX and TCZ on the expression of
Table 1 Ranking of the candidate housekeeping genes according to their expression stability values calculated by geNorm,
NormFinder and BestKeeper algorithms
Gene geNorm NormFinder BestKeeper
Ranking order Symbol Expression stability (M) Stability value Correlation coefficient (r)
CD4+
1 GAPDH 1.152 0.080 0.898
2 HPRT1 1.254 0.256 0.814
3 ACTB 1.520 0.297 0.890
CD8+
1 GAPDH 1.345 0.139 0.973
2 HPRT1 1.457 0.283 0.945
3 ACTB 1.498 0.281 0.971
CD14+
1 GAPDH 1.470 0.123 0.978
2 ACTB 1.521 0.148 0.981
3 HPRT1 1.623 0.178 0.964
CD19+
1 GAPDH 1.524 0.191 0.965
2 HPRT1 1.658 0.322 0.951
3 ACTB 1.796 0.342 0.964
DC
1 GAPDH 1.164 0.124 0.950
2 HPRT1 1.310 0.310 0.889
3 ACTB 1.429 0.297 0.944
PBMCs
1 GAPDH 1.239 0.085 0.887
2 HPRT1 1.351 0.224 0.748
3 ACTB 1.651 0.259 0.862
ACTB, beta-actin; DC, dendritic cell; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HPRT1, hypoxanthine guanine phosphoribosyl
transferase 1; PBMCs, peripheral blood mononuclear cells.
Bold format was applied for stability values of the most stable housekeeping genes (GAPDH).
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immunoproteasome subunits, paired one-way ANOVA
with Tukey’s multiple comparison test (95% CI) was
applied to whole-blood expression data before and
during therapy. GraphPad Prism 7 software (San
Diego, California, USA) was used for all statistical ana-
lysis and statistical significance was set at p<0.05.
RESULTS
A total of 40 patients (31 women and 9 men) with a mean
age of 58 years (SD±12 years; median 58 years, range
26–78 years) diagnosed with RA were included in the
study. One patient was enrolled in the biomarker project
at T0 but did not receive abatacept treatment; therefore,
the biomarker follow-up analyses were only done in 39
patients. Twenty-nine were rheumatoid factor (RF)-IgM-
positive and 28 were anti-citrullinated protein antibodies
(ACPA)-positive. Disease duration ranged between
3months and 45 years (mean 7.6 years). Thirty-five patients
received abatacept as the first biological therapy after fail-
ure of MTX and two patients as first line together with
MTX. Previous therapy included MTX in 27 patients, leflu-
nomide in 17 patients, sulfasalazine in 8 patients, hydroxy-
chloroquine in 5 patients and azathioprine in 2 patients.
Previous biological therapies included TCZ (three
patients), rituximab, adalimumab, certolizumab and eta-
nercept (two patients each) and anakinra (one patient).
Twenty-three patients received abatacept intrave-
nously, while 16 patients received abatacept subcuta-
neously. Prednisolone was given as a comedication in
31 patients (21 up to 5 mg/day, 6 patients between 5
and 10 mg/day and 4 more than 10 mg/day). Addi-
tional concomitant DMARDs included hydroxychlor-
oquine (seven patients), leflunomide (six patients)
and sulfasalazine (five patients). Thirty-two patients
reached T16, while 29 patients completed the goal of
6 months of treatment (T24).
Disease activity of RA was evaluated according to
the EULAR response criteria (table 2). According to
a change in DAS28-ESR of >1.2 from T0 to T16 or
T24, four different groups were defined: prolonged
responder at T16 and T24 (RT16RT24) (n=12),
responder at T16 and NR at T24 (RT16NRT24)
(n=3), responder at T24 and NR at T16
(RT24NRT16) (n=8) and NR (n=6). Eight patients
discontinued intervention at T16 and three at T24,
as shown in figure 1.
Abatacept significantly reduced the expression of proteasomal
immunosubunit β1i in T lymphocytes
After sorting patients into four groups according to treat-
ment response, we investigated the influence of abatacept
on the expression of proteasome subunits by using paired
two-way ANOVA.
Using real-time RT-PCR, we investigated the expres-
sion of proteasomal subunits β1, β2, β5, β1i, β2i, β5i
and α3 at three time points, T0, T16 and T24, in CD4+,
CD8+ T lymphocytes, CD14+ monocytes, CD19+
B lymphocytes, DCs and total PBMCs of patients. To
investigate if there was an effect of abatacept on the
expression of proteasome subunits and if this effect
depended on the degree of response, two-way repeated
measure ANOVA was applied. Thus, two factors were
time (T0, T16 and T24) and type of response (response
at both time points week 16 and week 24 (RT16RT24),
response at time point week 16 but not at week 24
(RT16NRT24), response at week 24 but non-response
at time point week 16 (RT24NRT16) and non-response
(NR)). After performing analysis in all cell subsets for all
subunits, only CD4+ and CD8+ T lymphocytes showed
significant interaction for immunosubunit β1i. In detail,
in both cell subsets, neither time nor response showed
solely effect on the expression of β1i; only the interaction
of both factors was statistically significant with reduced
expression of immunosubunit β1i in prolonged response
group RT16RT24 at T24 (F(6, 42)=2.468 p=0.0390
for CD4+ (figure 2), F(6, 40)=2.882 p=0.0198 for CD8+
(figure 3).
To confirm the result, we applied one-way repeated
measure ANOVA for each response group separately
Table 2 Patients in remission, low,moderate or high disease activities according to EULAR response criteria usingDAS28-ESR
Remission Low Moderate High Total
DAS28-ESR <2.6 ≥2.6 and ≤3.2 >3.2 and ≤5.1 >5.1
T0 (n) 3 (7.7%) 27 (69.2%) 10 (25.6%) 39
T16 (n) 13 (40.6%) 5 (15.6%) 13 (40.6%) 1 (3.1%) 32
T24 (n) 14 (48.3%) 6 (20.7%) 6 (20.7%) 3 (10.3%) 29
DAS28-ESR, 28-joint disease activity score based on erythrocyte sedimentation rate; T0, baseline; T16, week 16; T24, week 24.
Figure 1 Flow of patients included in the study. Number
of patients and reason for discontinuation and number of
samples analysed per time point.
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with three time points in CD4+ andCD8+. The expression
of β1i was significantly reduced in prolonged responders
RT16RT24 at T24 in CD4+ (F(1.185, 11.85)=8.751
p=0.0098); in addition, Tukey’s multiple comparison
test showed significant differences between T0 and T24
(p=0.0396) and between T16 and T24 (p=0.0260,
figure 4). CD8+ showed also significant reduction at T24
(F(1.359, 13.59)=5.968, p=0.0215, figure 5).
Additionally, we applied ordinary (not repeated mea-
sures) one-way ANOVA for each time with four different
response groups and there was no significant difference
between groups at each time point.
Abatacept does not have significant influence on serum IFN-γ
Patients were sorted into four response groups and two-
way repeated measure ANOVA was applied to analyse the
influence of abatacept on the concentration of serum
IFN-γ during time of therapy regarding response rate.
No significant interaction was detected; also the main
effect of time or response rate on serum IFN-γ was not
statistically significant (data not shown).
Methotrexate, infliximab and tocilizumab show no effect on
immunoproteasome subunits
To estimate effects of MTX on the expression of immu-
noproteasome subunits and to compare the effect of
abatacept on proteasome with other bDMARDs (IFX
and TCZ), we investigated the open-access data
(GSE93777) for expression of immunoproteasome sub-
units β1i, β2i and β5i in whole-blood transcriptomes,
which were available from multiple time points for
three groups of RA responders, who were treated with
MTX, IFX or TCZ. Samples were grouped according to
time points (T0, mid and end of treatment) and paired
one-way ANOVA was applied to estimate the effect of
each of these treatments on immunoproteasome subu-
nits expression. No significant changes were detected in
any of the treatment groups (figure 6).
Abatacept does not influence β5i chymotrypsin-like activity of
proteasome
To assess the therapeutic effect on the activity of the
proteasome, we measured proteasome activity at
three time points using bortezomib (proteasome
inhibitor) as a tool to specifically determine protea-
some activity. Since only a limited amount of material
was available, we focused one proteolytic activity and
selected the most common chymotrypsin-like one
(carried out by β5i). The activity of the lysates incu-
bated with bortezomib (5 and 50 nM) was measured
and normalised based on the activity of cell lysates
without proteasome inhibitor which was set as 100%.
To estimate this effect and to assess if there was
a difference dependent on response state, ordinary
(not repeated measures) two-way ANOVA was applied
using time and response rates as two independent
factors and proteasome activity as the dependent
Figure 3 Proteasomal immunosubunit β1i was significantly
different in T lymphocytes CD8+ depending on response to
therapy. Relative gene expression of proteasomal subunits
normalised to GAPDH in CD8+ T lymphocytes. Patients
were sorted into four groups according to response rate and
the effect of abatacept on the expression of proteasomal
subunits during 6 months was analysed. The bar plots
represent the mean with SD. Two-way repeated ANOVA
with Tukey’s multiple comparison test was performed on
log-transformed data using GraphPad Prism 7. ANOVA,
analysis of variance; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; RT16RT24, response at both time points
week 16 and week 24; RT16NRT24, response at time
point week 16 but not at week 24; RT24NRT16, response
at week 24 but non-response at time point week 16; NR,
non-response. T0, baseline; T16, at 16 weeks; T24, at
24 weeks. *p<0.05.
Figure 2 Proteasomal immunosubunit β1i was significantly
different in T lymphocytes CD4+ depending on response to
therapy. Relative gene expression of proteasomal subunits
normalised to GAPDH in CD4+ T lymphocytes. Patients
were sorted into four groups according to response rate and
the effect of abatacept on the expression of proteasomal
subunits during 6 months was analysed. The bar plots
represent the mean with SD. Two-way repeated ANOVA
with Tukey’s multiple comparison test was performed on
log-transformed data using GraphPad Prism 7. ANOVA,
analysis of variance; GAPDH, glyceraldehyde-3-phosphate
dehydrogenase; RT16RT24, response at both time points
week 16 and week 24; RT16NRT24, response at time point
week 16 but not at week 24; RT24NRT16, response at
week 24 but non-response at time point week 16; NR,
non-response. T0, baseline; T16, at 16 weeks; T24, at
24 weeks. *p<0.05.
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variable in the analysis. Experiments were only per-
formed in PBMCs and CD4+ and CD8+ cells in sam-
ples with sufficient cell counts and in three groups
RT16RT24, RT24NRT16 and NR. RT16NRT24 group
was excluded because of limited data available due to
low number of patients in this group (n=3). A dose-
dependent effect just for proteasome activity was
observed in all cells. After using 5 nM bortezomib,
there was no statistically significant interaction
between the response rate and different time points
on proteasome activity in PBMCs (F(4, 54)=0.05071,
p=0.9950), in CD4+ (F(4, 34)=0.4666, p=0.7598) and
in CD8+ (F(4, 18)=1.32, p=0.3002). After using
50 nM bortezomib, the interaction was also not sig-
nificant in PBMCs (F(4, 54)=1.006, p=0.4127) and in
CD4+ (F(4, 32)=0.6064, p=0.6609). For CD8+, the
available data was not enough to perform analysis.
The main effect for different times and for different
response rates on proteasome activity was also not statis-
tically significant in PMBCs, CD4+ and CD8+ after using
5 nM bortezomib and in PMBCs and CD4+ after
using 50 nM bortezomib (data not shown).
Figure 5 Responders at T16 and T24 showed significant
reduction in β1i in CD8+ T lymphocytes. Relative gene
expression of immunoproteasomal subunit β1i normalised
to GAPDH in CD8+ T lymphocytes. Patients were sorted
into four groups according to response rate and the effect
of abatacept on the expression of immunoproteasomal
subunit β1i during 6 months was analysed for each group
separately. The lines represent mean with SD. One-way
repeated ANOVA with Tukey’s multiple comparison test
was performed on log-transformed data using GraphPad
Prism 7. ANOVA, analysis of variance; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; RT16RT24,
response at both time points week 16 and week 24;
RT16NRT24, response at time point week 16 but not at
week 24; RT24NRT16, response at week 24 but
non-response at time point week 16; NRT16NRT24,
non-response. T0, baseline; T16, at 16 weeks; T24, after
24 weeks. *p<0.05.
Figure 6 Rheumatoid arthritis (RA) responders show no
changes in immunoproteasome subunits under the effect of
methotrexate (MTX), infliximab (IFX) or tocilizumab (TCZ)
treatment. The expression of immunoproteasome subunits
β1i, β2i and β5i was investigated in whole-blood transcriptome
data (GSE93777) at multiple times for three groups of RA
responders treated with MTX, IFX or TCZ for 6 months. Data
were sorted according to time points (baseline (T0), mid (T2)
and end of treatment (T3)) and paired one-way analysis of
variance was applied on log-transformed data
using GraphPad Prism 7. No significant changes were
detected in any of the treatment groups.
Figure 4 Responders at T16 and T24 showed significant
reduction in β1i in CD4+ T lymphocytes. Relative gene
expression of immunoproteasomal subunit β1i normalised
to GAPDH in CD4+ T lymphocytes. Patients were sorted
into four groups according to response rate and the effect
of abatacept on the expression of immunoproteasomal
subunit β1i during 6 months was analysed for each group
separately. The lines represent mean with SD. One-way
repeated ANOVA with Tukey’s multiple comparison test
was performed on log-transformed data using GraphPad
Prism 7. ANOVA, analysis of variance; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; RT16RT24,
response at both time points week 16 and week 24;
RT16NRT24, response at time point week 16 but not at
week 24; RT24NRT16, response at week 24 but
non-response at time point week 16; NRT16NRT24,
non-response. T0, baseline; T16, at 16 weeks; T24, at
24 weeks. *p<0.05, **p<0.01.
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Abatacept has no effect on the induction of apoptosis by
proteasome inhibitor
To examine if there was any effect of abatacept on protea-
some in enhancing or suppressing the role of proteasome
inhibitor in inducing apoptosis, caspase activity was mea-
sured in cells incubated with 5 and 50 nM bortezomib and
data were normalised based on the caspase activity in cells
without proteasome inhibitor, which was set as 1.00. For
analysis, ordinary (not repeated measures) two-way
ANOVA was performed, time and different response
groups were two independent factors and apoptosis was
the dependent variable. PBMCs, CD4+ and CD8+ of sam-
ples with sufficient cell counts were used and the analyses
were performed in three response groups RT16RT24,
RT24NRT16 and NR. RT16NRT24 group was excluded
because of limited data available due to low number of
patients in this group (n=3). A dose-dependent effect just
for induction of apoptosis was observed in all cells. After
incubation of cells with 5 nM bortezomib, there was no
statistically significant interaction between the response
rate and different time points on apoptosis in PBMCs (F
(4, 57)=0.544, p=0.7041), in CD4+ (F(4, 44)=0.6271,
p=0.6457) and in CD8+ (F(4, 27)=1.447, p=0.2458). After
using 50 nM bortezomib, the interaction was also not
significant in PBMCs (F (4, 59)=1.057, p=0.3860), in
CD4+ (F(4, 49)=1.712, p=0.1624) and in CD8+ (F(4, 29)
=2.314, p=0.0812). The main effect for different times and
for different response rates on proteasome activity was also
not statistically significant in PMBCs, CD4+ and CD8+
after using 5 nM and 50 nM bortezomib (data not shown).
DISCUSSION
In this study, we were able to show that only a successful
treatment with abatacept had an influence on the
expression of the proteasome system in patients with RA.
In fact, a significant reduction of the expression of the
immunosubunit β1i was observed exclusively in CD4+
and CD8+ T lymphocytes only in patients with
a prolonged response over 24 weeks of treatment. This
effect is consistent with the mode of action of abatacept
as a costimulationmodulator and inhibitor of T cell activa-
tion. This result is of interest since the main goal in RA
treatment is to achieve clinical remission or very low dis-
ease activity.30 In this context, it is important to understand
also the biochemical correlation of disease remission and
to characterise the involved pathways in more detail.31
In our study, 87% of patients received abatacept as the
first bDMARD and 5% as first-line therapy. As a result,
55% achieved remission or low disease activity at week 16
and 70% at week 24 confirming the excellent effective-
ness of abatacept especially in bDMARDs-naïve patients.
In this context, our observations are in line with the
results from the clinical development programme of aba-
tacept with best results in early phases of disease and in
patients without prior exposure to bDMARDs.32 33
Methodically, we used relative quantification real-time
PCR to evaluate the expression of different catalytic
proteasomal subunits in different cell subsets relative to
HKGs used for normalisation of the target gene expres-
sion. Since the expression levels of HKGs vary between
cell types and experimental conditions,34 the selection of
the most stable reference gene is important to assure the
accuracy of results obtained in the analysis. According to
previous studies,35 we evaluate the stability of commonly
used HKGs using three algorithms. Consistent with
results obtained previously in PBMCs,35 GAPDH was the
most stable reference gene across all cell subsets used in
this analysis.
In the former study, a significant decrease in the per-
centage of IFN-γ-producing CD8+ T cells was detected in
patients with RA administrated with abatacept for
6 months. Of note, when patients were stratified accord-
ing to their clinical response, this reduction was statisti-
cally significant only in patients with good response.21
This was confirmed by another study showing
a reduction of the level of IFN-γ in serum36 and
a reduced expression in synovial cells37 under abatacept
therapy. Obviously, in vitro treatment of synovial T cells
with abatacept decreased their ability to produce IFN-γ.38
As also reported previously, the reduction of IFN-γ pro-
duction can be associated with a good clinical response to
abatacept.37 Our results are partly in line with these
known associations; thus, on the one hand, the expres-
sion analysis did show a significant decrease for the β1i
subunit only in CD4+ and CD8+ of prolonged response
patients; on the other hand, no significant difference of
serum IFN-γ or association between response rate and
IFN-γ could be detected in our patients. This finding is
in agreement with our results that neither β2i nor β5i
showed a significant decrease in any cell subset. Accord-
ingly, we could suspect that the reduction of β1i in our
prolonged responders was not under the effect of IFN-γ,
although the measurement of cellular IFN-γ could have
confirmed the conclusion. This interesting observation
supports further research on the proteasome system in
patients with RA under abatacept treatment as well as
in vitro cell culture experiments on the proteasome sys-
tem in the presence/absence of abatacept to replicate the
in vivo findings.
Analysis of whole-blood transcriptomes of RA respon-
ders to MTX, IFX and TCZ was performed as a first
approach to compare with other types of therapies in
RA. Although no cell subset data could be investigated,
these data did not show any effect of MTX, IFX and TCZ
on immunoproteasome subunits. Next, we estimated the
effect of abatacept on the activity of proteasome and
immunoproteasome by using bortezomib. This potent
reversible proteasome inhibitor primarily targets the β5
subunits with chymotrypsin-like activity, whereas the β1
subunit and its immunoproteasome counterpart β1i with
caspase-like activity are less specifically inhibited.39 Due to
limited material, we applied only chymotrypsin-specific
substrate to measure the remaining chymotrypsin-like
activity, which is considered to represent the most impor-
tant active site in protein breakdown40 and exhibits an
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increasing activity under the effect of IFN-γ.41 In fact, all
three active sites contribute significantly to protein break-
down. Thus, simultaneous inhibition of the chymotryp-
sin-like and the caspase-like as well as trypsin-like sites is
required to markedly decrease proteolysis.39 However, in
our study, only the expression of β1i was significantly
influenced in responders under abatacept. Therefore,
we were unable to show an influence on the β5i-
dependent proteolytic activity.
The transcription factor nuclear factor-kappa B (NF-κB)
is a well-known regulator of inflammation in RA.42 In
unstimulated cells, NF-κB is present in the cytoplasm in
a latent form bound to inhibitory proteins known as IκB.
Activation of NF-κB involves phosphorylation, ubiquitina-
tion and proteasomal degradation of IκB, allowing the
transcription factor to enter the nucleus and initiate
transcription.43 As known, the proteasome inhibitor bor-
tezomib inhibits NF-κB by blocking degradation of IκB44;
additionally, many studies confirmed the role of NF-κB in
apoptosis mediated by proteasome inhibitors.45 46 There-
fore, in this study, we tried to investigate the effect of
bortezomib on apoptosis in T cells of patients with RA
after exposure to abatacept. However, we did not observe
any influence of abatacept on susceptibility of cells to
apoptosis under the influence of bortezomib. Other stu-
dies have confirmed an association between immunosu-
bunits and enhanced activation of the NF-κB pathway.47
In addition, a downregulation of the NF-κB cascade was
shown inmacrophages treated with abatacept in vivo.48 In
our patients, the exclusive reduction of β1i was obviously
not sufficient to introduce a strong effect, or the reduc-
tion in β1i could have been compensated via constitutive
subunits as seen after β5i blocking previously.49 In this
context, it is also known that immunoproteasome inhibi-
tors can rather reduce the extracellular signal-regulated
kinase (ERK) phosphorylation cascade but not the NF-κB
pathway.49
CONCLUSION
In summary, treatment with abatacept showed a clear
effect exclusively on the expression of the IFN-inducible
proteasome immunosubunit β1i, but surprisingly not on
other immunosubunits.
This finding is especially of interest since this phenom-
enon was only seen in CD4+ and CD8+ T cells of pro-
longed responding patients with RA. Taken together, we
describe an association between reduced induction of
β1i and sustained response to the T-cell-directed therapy
with abatacept. Thus, the role of the proteasome subunit
β1i in T cell activation in RA should be investigated in
future studies.
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